MAKAP - A master scaffold for cardiac remodeling

Journal of Cardiovascular Pharmacology

Volumn 65, Issue 3, 2015, Pages 218-225

  Passariello, Catherine L ^a   Li, Jinliang ^a   Dodge Kafka, Kimberly ^b   Kapiloff, Michael S ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

heart; mAKAP; nuclear envelope; remodeling; signalosome

Indexed keywords

CALCIUM; CYCLIC AMP; HISTONE DEACETYLASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MAKAP BETA PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MYOCYTE ENHANCER FACTOR 2; PHOSPHATIDYLINOSITIDE; PROTEIN; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG; AKAP6 PROTEIN, HUMAN; CYCLIC AMP DEPENDENT PROTEIN KINASE ANCHORING PROTEIN;

ADAPTATION; CALCIUM SIGNALING; GENE EXPRESSION; HEART MUSCLE CELL; HEART VENTRICLE REMODELING; HUMAN; HYPOXIA; INTRACELLULAR SIGNALING; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; CARDIAC MUSCLE CELL; CARDIOMEGALY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY;

A KINASE ANCHOR PROTEINS; ANIMALS; CARDIOMEGALY; HUMANS; MYOCYTES, CARDIAC; SIGNAL TRANSDUCTION; VENTRICULAR REMODELING;

EID: 84925535523     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000206     Document Type: Review

References (79)

1. Burchfield JS, Xie M, Hill JA. Pathological ventricular remodeling: mechanisms: part 1 of 2. Circulation. 2013;128:388-400.
2. Sharma K, Kass DA. Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies. Circ Res. 2014;115:79-96.
3. Heineke J, Molkentin JD. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol. 2006;7:589-600.
4. Clerk A, Cullingford TE, Fuller SJ, et al. Signaling pathways mediating cardiac myocyte gene expression in physiological and stress responses. J Cell Physiol. 2007;212:311-322.
5. Scott JD, Pawson T. Cell signaling in space and time: where proteins come together and when they're apart. Science. 2009;326:1220-1224.
6. Pawson T, Nash P. Assembly of cell regulatory systems through protein interaction domains. Science. 2003;300:445-452.
7. Good MC, Zalatan JG, Lim WA. Scaffold proteins: hubs for controlling the flow of cellular information. Science. 2011;332:680-686.
8. Kritzer MD, Li J, Passariello CL, et al. The scaffold protein muscle A-kinase anchoring protein beta orchestrates cardiac myocyte hypertrophic signaling required for the development of heart failure. Circ Heart Fail. 2014;7:663-672.
9. McCartney S, Little BM, Langeberg LK, et al. Cloning and characterization of A-kinase anchor protein 100 (AKAP100). A protein that targets A-kinase to the sarcoplasmic reticulum. J Biol Chem. 1995;270: 9327-9333.
10. Kapiloff MS, Schillace RV, Westphal AM, et al. mAKAP: an A-kinase anchoring protein targeted to the nuclear membrane of differentiated myocytes. J Cell Sci. 1999;112:2725-2736.
11. Michel JJ, Townley IK, Dodge-Kafka KL, et al. Spatial restriction of PDK1 activation cascades by anchoring to mAKAPalpha. Mol Cell. 2005;20:661-672.
12. Pare GC, Easlick JL, Mislow JM, et al. Nesprin-1alpha contributes to the targeting of mAKAP to the cardiac myocyte nuclear envelope. Exp Cell Res. 2005;303:388-399.
13. Bonne G, Di Barletta MR, Varnous S, et al. Mutations in the gene encoding lamin A/C cause autosomal dominant Emery-Dreifuss muscular dystrophy. Nat Genet. 1999;21:285-288.
14. Fatkin D, MacRae C, Sasaki T, et al. Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. N Engl J Med. 1999;341:1715-1724.
15. Muchir A, Bonne G, van der Kooi AJ, et al. Identification of mutations in the gene encoding lamins A/C in autosomal dominant limb girdle muscular dystrophy with atrioventricular conduction disturbances (LGMD1B). Hum Mol Genet. 2000;9:1453-1459.
16. Bione S, Maestrini E, Rivella S, et al. Identification of a novel X-linked gene responsible for Emery-Dreifuss muscular dystrophy. Nat Genet. 1994;8:323-327.
17. Zhang Q, Bethmann C, Worth NF, et al. Nesprin-1 and-2 are involved in the pathogenesis of Emery Dreifuss muscular dystrophy and are critical for nuclear envelope integrity. Hum Mol Genet. 2007; 16:2816-2833.
18. Zhang L, Malik S, Kelley GG, et al. Phospholipase C epsilon scaffolds to muscle-specific A kinase anchoring protein (mAKAPbeta) and integrates multiple hypertrophic stimuli in cardiac myocytes. J Biol Chem. 2011; 286:23012-23021.
19. Marx SO, Reiken S, Hisamatsu Y, et al. PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell. 2000;101:365-376.
20. Yang J, Drazba JA, Ferguson DG, et al. A-kinase anchoring protein 100 (AKAP100) is localized in multiple subcellular compartments in the adult rat heart. J Cell Biol. 1998;142:511-522.
21. Kapiloff MS, Jackson N, Airhart N. mAKAP and the ryanodine receptor are part of a multi-component signaling complex on the cardiomyocyte nuclear envelope. J Cell Sci. 2001;114:3167-3176.
22. Pare GC, Bauman AL, McHenry M, et al. The mAKAP complex participates in the induction of cardiac myocyte hypertrophy by adrenergic receptor signaling. J Cell Sci. 2005;118:5637-5646.
23. Dodge-Kafka KL, Soughayer J, Pare GC, et al. The protein kinase A anchoring protein mAKAP coordinates two integrated cAMP effector pathways. Nature. 2005;437:574-578.
24. Deleted in press.
25. Wong W, Goehring AS, Kapiloff MS, et al. mAKAP compartmentalizes oxygen-dependent control of HIF-1alpha. Sci Signal. 2008;1:ra18.
26. Dodge-Kafka KL, Kapiloff MS. The mAKAP signaling complex: integration of cAMP, calcium, and MAP kinase signaling pathways. Eur J Cell Biol. 2006;85:593-602.
27. Vargas MA, Tirnauer JS, Glidden N, et al. Myocyte enhancer factor 2 (MEF2) tethering to muscle selective A-kinase anchoring protein (mAKAP) is necessary for myogenic differentiation. Cell Signal. 2012;24: 1496-1503.
28. Faul C, Dhume A, Schecter AD, et al. Protein kinase A, Ca2+/calmodulin-dependent kinase II, and calcineurin regulate the intracellular trafficking of myopodin between the Z-disc and the nucleus of cardiac myocytes. Mol Cell Biol. 2007;27:8215-8227.
29. Schulze DH, Muqhal M, Lederer WJ, et al. Sodium/calcium exchanger (NCX1) macromolecular complex. J Biol Chem. 2003; 278:28849-28855.
30. Kapiloff MS, Piggott LA, Sadana R, et al. An adenylyl cyclasemAKAPbeta signaling complex regulates cAMP levels in cardiac myocytes. J Biol Chem. 2009;284:23540-23546.
31. Zhang L, Malik S, Pang J, et al. Phospholipase Cepsilon hydrolyzes perinuclear phosphatidylinositol 4-phosphate to regulate cardiac hypertrophy. Cell. 2013;153:216-227.
32. Li J, Vargas MA, Kapiloff MS, et al. Regulation of MEF2 transcriptional activity by calcineurin/mAKAP complexes. Exp Cell Res. 2013;319: 447-454.
33. Li J, Negro A, Lopez J, et al. The mAKAPbeta scaffold regulates cardiac myocyte hypertrophy via recruitment of activated calcineurin. J Mol Cell Cardiol. 2010;48:387-394.
34. Kritzer MD, Li J, Dodge-Kafka K, et al. AKAPs: the architectural underpinnings of local cAMP signaling. J Mol Cell Cardiol. 2012; 52:351-358.
35. Newlon MG, Roy M, Morikis D, et al. The molecular basis for protein kinase A anchoring revealed by solution NMR. Nat Struct Biol. 1999;6: 222-227.
36. Zakhary DR, Fink MA, Ruehr ML, et al. Selectivity and regulation of Akinase anchoring proteins in the heart. The role of autophosphorylation of the type II regulatory subunit of cAMP-dependent protein kinase. J Biol Chem. 2000;275:41389-41395.
37. Dodge KL, Khouangsathiene S, Kapiloff MS, et al. mAKAP assembles a protein kinase A/PDE4 phosphodiesterase cAMP signaling module. EMBO J. 2001;20:1921-1930.
38. Scott JD, Dessauer CW, Tasken K. Creating order from chaos: cellular regulation by kinase anchoring. Annu Rev Pharmacol Toxicol. 2013;53: 187-210.
39. Sette C, Conti M. Phosphorylation and activation of a cAMP-specific phosphodiesterase by the cAMP-dependent protein kinase. Involvement of serine 54 in the enzyme activation. J Biol Chem. 1996;271: 16526-16534.
40. Carlisle Michel JJ, Dodge KL, Wong W, et al. PKA-phosphorylation of PDE4D3 facilitates recruitment of the mAKAP signalling complex. Biochem J. 2004;381:587-592.
41. Hoffmann R, Baillie GS, MacKenzie SJ, et al. The MAP kinase ERK2 inhibits the cyclic AMP-specific phosphodiesterase HSPDE4D3 by phosphorylating it at Ser579. EMBO J. 1999;18:893-903.
42. Mackenzie KF, Topping EC, Bugaj-Gaweda B, et al. Human PDE4A8, a novel brain-expressed PDE4 cAMP-specific phosphodiesterase that has undergone rapid evolutionary change. Biochem J. 2008;411:361-369.
43. Dodge-Kafka KL, Bauman A, Mayer N, et al. cAMP-stimulated protein phosphatase 2A activity associated with muscle A kinase-anchoring protein (mAKAP) signaling complexes inhibits the phosphorylation and activity of the cAMP-specific phosphodiesterase PDE4D3. J Biol Chem. 2010;285:11078-11086.
44. Ahn JH, McAvoy T, Rakhilin SV, et al. Protein kinase A activates protein phosphatase 2A by phosphorylation of the B56delta subunit. Proc Natl Acad Sci U S A. 2007;104:2979-2984.
45. Rababa'h A, Craft JW Jr, Wijaya CS, et al. Protein kinase A and phosphodiesterase-4D3 binding to coding polymorphisms of cardiac muscle anchoring protein (mAKAP). J Mol Biol. 2013;425:3277-3288.
46. Nicol RL, Frey N, Pearson G, et al. Activated MEK5 induces serial assembly of sarcomeres and eccentric cardiac hypertrophy. EMBO J. 2001;20:2757-2767.
47. Kimura TE, Jin J, Zi M, et al. Targeted deletion of the extracellular signal-regulated protein kinase 5 attenuates hypertrophic response and promotes pressure overload-induced apoptosis in the heart. Circ Res. 2010;106:961-970.
48. Ranganathan A, Pearson GW, Chrestensen CA, et al. The MAP kinase ERK5 binds to and phosphorylates p90 RSK. Arch Biochem Biophys. 2006;449:8-16.
49. Anjum R, Blenis J. The RSK family of kinases: emerging roles in cellular signalling. Nat Rev Mol Cell Biol. 2008;9:747-758.
50. Sadoshima J, Qiu Z, Morgan JP, et al. Angiotensin II and other hypertrophic stimuli mediated by G protein-coupled receptors activate tyrosine kinase, mitogen-activated protein kinase, and 90-kD S6 kinase in cardiac myocytes. The critical role of Ca(2+)-dependent signaling. Circ Res. 1995;76:1-15.
51. Takeishi Y, Huang Q, Abe J, et al. Activation of mitogen-activated protein kinases and p90 ribosomal S6 kinase in failing human hearts with dilated cardiomyopathy. Cardiovasc Res. 2002;53:131-137.
52. Li J, Kritzer MD, Michel JJ, et al. Anchored p90 ribosomal S6 kinase 3 is required for cardiac myocyte hypertrophy. Circ Res. 2013;112: 128-139.
53. Passariello CL, Gayanilo M, Kritzer MD, et al. p90 ribosomal S6 kinase 3 contributes to cardiac insufficiency in alpha-tropomyosin Glu180Gly transgenic mice. Am J Physiol Heart Circ Physiol. 2013; 305:H1010-H1019.
54. Monovich L, Vega RB, Meredith E, et al. A novel kinase inhibitor establishes a predominant role for protein kinase D as a cardiac class IIa histone deacetylase kinase. FEBS Lett. 2010;584:631-637.
55. Xie M, Hill JA. HDAC-dependent ventricular remodeling. Trends Cardiovasc Med. 2013;23:229-235.
56. Valdivia HH, Kaplan JH, Ellis-Davies GC, et al. Rapid adaptation of cardiac ryanodine receptors: modulation by Mg2+ and phosphorylation. Science. 1995;267:1997-2000.
57. Dulhunty AF, Beard NA, Pouliquin P, et al. Agonists and antagonists of the cardiac ryanodine receptor: potential therapeutic agents? Pharmacol Ther. 2007;113:247-263.
58. Bers DM. Cardiac ryanodine receptor phosphorylation: target sites and functional consequences. Biochem J. 2006;396:e1-e3.
59. Houser SR. Role of RyR2 phosphorylation in heart failure and arrhythmias: protein kinase A-mediated hyperphosphorylation of the ryanodine receptor at serine 2808 does not alter cardiac contractility or cause heart failure and arrhythmias. Circ Res. 2014;114:1320-1327; discussion 7.
60. Dobrev D, Wehrens XH. Role of RyR2 phosphorylation in heart failure and arrhythmias: controversies around ryanodine receptor phosphorylation in cardiac disease. Circ Res. 2014;114:1311-1319; discussion 9.
61. Escobar M, Cardenas C, Colavita K, et al. Structural evidence for perinuclear calcium microdomains in cardiac myocytes. J Mol Cell Cardiol. 2011;50:451-459.
62. Bueno OF, Wilkins BJ, Tymitz KM, et al. Impaired cardiac hypertrophic response in Calcineurin Abeta-deficient mice. Proc Natl Acad Sci U S A. 2002;99:4586-4591.
63. Bueno OF, Lips DJ, Kaiser RA, et al. Calcineurin Abeta gene targeting predisposes the myocardium to acute ischemia-induced apoptosis and dysfunction. Circ Res. 2004;94:91-99.
64. Wilkins BJ, Dai YS, Bueno OF, et al. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ Res. 2004;94:110-118.
65. Kim Y, Phan D, van Rooij E, et al. The MEF2D transcription factor mediates stress-dependent cardiac remodeling in mice. J Clin Invest. 2008;118:124-132.
66. Wilkins BJ, De Windt LJ, Bueno OF, et al. Targeted disruption of NFATc3, but not NFATc4, Reveals an intrinsic defect in calcineurinmediated cardiac hypertrophic growth. Mol Cell Biol. 2002;22: 7603-7613.
67. Bourajjaj M, Armand AS, da Costa Martins PA, et al. NFATc2 is a necessary mediator of calcineurin-dependent cardiac hypertrophy and heart failure. J Biol Chem. 2008;283:22295-22303.
68. Potthoff MJ, Olson EN. MEF2: a central regulator of diverse developmental programs. Development. 2007;134:4131-4140.
69. Naya FJ, Wu C, Richardson JA, et al. Transcriptional activity of MEF2 during mouse embryogenesis monitored with a MEF2-dependent transgene. Development. 1999;126:2045-2052.
70. Naya FJ, Olson E. MEF2: a transcriptional target for signaling pathways controlling skeletal muscle growth and differentiation. Curr Opin Cell Biol. 1999;11:683-688.
71. Black BL, Olson EN. Transcriptional control of muscle development by myocyte enhancer factor-2 (MEF2) proteins. Annu Rev Cell Dev Biol. 1998;14:167-196.
72. Friday BB, Mitchell PO, Kegley KM, et al. Calcineurin initiates skeletal muscle differentiation by activating MEF2 and MyoD. Differentiation. 2003;71:217-227.
73. Wu H, Rothermel B, Kanatous S, et al. Activation of MEF2 by muscle activity is mediated through a calcineurin-dependent pathway. EMBO J. 2001;20:6414-6423.
74. Kato Y, Zhao M, Morikawa A, et al. Big mitogen-activated kinase regulates multiple members of the MEF2 protein family. J Biol Chem. 2000; 275:18534-18540.
75. Wang X, Tang X, Li M, et al. Regulation of neuroprotective activity of myocyte-enhancer factor 2 by cAMP-protein kinase A signaling pathway in neuronal survival. J Biol Chem. 2005;280:16705-16713.
76. Backs J, Worst BC, Lehmann LH, et al. Selective repression of MEF2 activity by PKA-dependent proteolysis of HDAC4. J Cell Biol. 195:403-415.
77. Ohh M, Park CW, Ivan M, et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol. 2000;2:423-427.
78. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;399:271-275.
79. Go AS, Mozaffarian D, Roger VL, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation. 2014;129:e28-e292.